Halofuginone reduces the occurrence of renal fibrosis in 5/6 nephrectomized rats

Israel Medical Association Journal

Volumn 9, Issue 1, 2007, Pages 30-34

  Benchetrit, Sydney ^a   Yarkoni, Shy ^d   Rathaus, Mauro ^a   Pines, Marc ^c   Rashid, Gloria ^a   Bernheim, Joelle ^a,b   Bernheim, Jacques ^a  

^a MEIR MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c VOLCANI CENTER   (Israel)

^d Medica L P   (Israel)

Author keywords

Collagen I; Fibrosis; Halofuginone; Nephrectomy; Rat

Indexed keywords

COLLAGEN TYPE 1; HALOFUGINONE; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE MONITORING; BODY WEIGHT; CONTROLLED STUDY; CREATININE CLEARANCE; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; GENE EXPRESSION; GLOMERULOSCLEROSIS; HISTOPATHOLOGY; IN SITU HYBRIDIZATION; KIDNEY FIBROSIS; MALE; NEPHRECTOMY; NONHUMAN; PROTEINURIA; RAT; STAINING;

ANIMALS; BLOOD PRESSURE; CASE-CONTROL STUDIES; DISEASE MODELS, ANIMAL; FIBROSIS; KIDNEY; MALE; NEPHRECTOMY; PIPERIDINES; PROTEIN SYNTHESIS INHIBITORS; PROTEINURIA; QUINAZOLINONES; RATS; RATS, WISTAR;

EID: 33846419532     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Klahr S, Schreiner G, Ichikawa I. The progression of renal disease. N Engl J Med 1988;318:1657-66.
2. Olson JL. Progression of renal disease, In: Olson JL, Schwartz MM, Silva FG, Jennette JC, eds. Heptinstall's Pathology of the Kidney. 5th edn. Philadelphia: Lippincot-Raven, 1998:137.
3. Halevy O, Nagler A, Levi-Shaffer F, et al. Inhibition of collagen type I synthesis by skin fibroblasts of graft versus host disease and scleroderma patients: effect of halofuginone. Biochem Pharmacol 1996;52:1057-63.
4. Nagler A, Katz A, Aingorn H, et al. Inhibition of glomerular mesangial cell proliferation and extracellular matrix deposition by halofuginone. Kidney Int 1997;52:1561-9.
5. Pines M, Nagler A. Halofuginone: a novel antifibrotic therapy. Gen Pharmacol 1998;30:445-50.
6. Nagler A, Pines M. Topical treatment of cutaneous chronic graft versus host disease (cGvHD) with halofuginone: a novel inhibitor of collagen type I synthesis. Transplantation 1999;68:1806-9.
7. Mc Gaha TL, Phelps RG, Spiera H, Bona C. Halofuginone, an inhibitor of type I collagen synthesis and skin sclerosis, blocks transforming-growth-factor-β-mediated Smad3 activation in fibroblasts. J Invest Dermatol 2002;118:461-70.
8. Watanabe N, Kamei S, Ohkubo A, et al. Urinary protein as measured with a pyrogallol red-molybdate complex, manually and in a Hitachi 726 automated analyzer. Clin Chem 1986;32:1551-4.
9. Zemin C, Burrel LM, Tikkanen I, et al. Vasopeptidase inhibition attenuates the progression of renal injury in subtotal nephrectomized rats. Kidney Int 2001;60:715-21.
10. Gascon-Barre M, Huet PM, Belgiorno J, Plourde V, Coulombe PA. Estimation of collagen content of liver specimens. Variation among animals and among hepatic lobes in cirrhotic rats. J Histochem Cytochem 1989;37:377-81.
11. Bruck R, Genina O, Aeed H, Alexiev R, Nagler A, Pines M. Halofuginone to prevent and treat thioacetamide-induced liver fibrosis in rats. Hepatology 2001;33:379-86.
12. Lupo A, Marcantoni C, Bernich P, et al. Resolution of renal disease: mission impossible? J Nephrol 2001;14:139-45.
13. Klahr S, Morrissey JJ. The role of vasoactive compounds, growth factors and cytakines in the progression of renal disease. Kidney Int 2000;57(Suppl 75):S7-14.
14. Mezzano SA, Ruiz-Ortega M, Egido J. Angiotensin II and renal fibrosis. Hypertension 2001;38(part 2):635-8.
15. Hebert LA, Wilmer WA, Falkenhain ME, et al. Renoprotection one or many therapies? Kidney Int 2001;59:1211-26.
16. Muller GA, Schettler V, Muller CA, Stratz F Prevention of progression of renal fibrosis: how far are we? Kidney Int 1996;49(Suppl 54):S75-82.
17. Rerolle JP, Hertig A, Nguyen G, et al, Plasminogen activator inhibitor type I is a potential target in renal fibrogenesis. Kidney Int 2000;58:1841-50.
18. Oda T, Jung YO, Kim HS, et al, PAI-1 deficiency attenuates the fibrogenic response to ureteral obstruction. Kidney Int 2001; 60:587-96.
19. Nagler A, Gofrit O, Ohana M, Pode D, Genina O, Pines M. The effect of halofuginone, an inhibitor of collagen type I synthesis, on urethral stricture formation: in vivo and in vitro study in a rat model. J Urol 2000;164:1776-80.
20. Shimizu T, Fukagawa M, Kuroda T, et al. Pirfenidone prevents collagen accumulation in the remnant kidney in rats with partial nephrectomy. Kidney Int 1997;52(Suppl 63):S239-43.
21. Gnainsky Y, Spira G, Paizi M, et al. Halofuginone, an inhibitor of collagen synthesis by rat stellate cells, stimulates insulin-like growth factor binding protein-1 synthesis by hepatocytes. J Hepatol 2004;40:269-77.
22. Oldroyd SID, Thomas GL, Gabbiani G, El Nahas AM. Interferon-gamma inhibits experimental renal fibrosis. Kidney Int 1999;56: 2116-27.